详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.

文献详情

资源类型：

作者：

机构： [1]School of Life Sciences and Technology, Tongji University, Shanghai, China [2]Shanghai Pulmonary Hospital, Shanghai, China [3]Tongji University Suzhou Institute, Suzhou, Jiangsu, China [4]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

出处：

DOI：

ISSN：

关键词： Circulating cell-free DNA lung cancer relapse surgery

摘要：

Cancer cells release DNA fragments into plasma as circulating free DNA (cfDNA). However, quantitative measurement of tumor-derived DNA in cfDNA remains challenge. The purpose of this study was to quantitatively assess tumor-derived DNA in lung cancer patients. By optimizing competitive allele-specific TaqMan PCR (CAST-PCR), we assessed the copy number of mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) alleles in the pre/post surgery plasma of 168 lung cancer patients. An absolute quantitative PCR method was developed to assess the number of total cfDNA. All mutations detected in tumors were also found in the plasma after surgery. At the time of 30 days after surgery, EGFR mutation of circulating cell-free DNA was detected only in two patients who recurred in 4 months after surgery. Compared to that of normal control at 30 days after surgery, five patients who recurred in 4 months had significantly higher circulating cell-free DNA (P < 0.001), whereas six patients who recurred after 4 months (P = 0.207) and five patients without recurrence (P = 0.901) demonstrated significantly lower circulating cell-free DNA. Our findings suggest that cfDNA analysis in plasma is an alternative and supplement to tissue analysis and hold promise for clinical application. Stratification of patients according to cfDNA levels at 30 days after surgery might be helpful in selecting lung cancer patients for adjuvant therapy after surgery. © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]School of Life Sciences and Technology, Tongji University, Shanghai, China

共同第一作者：

通讯作者：

通讯机构： [1]School of Life Sciences and Technology, Tongji University, Shanghai, China [2]Shanghai Pulmonary Hospital, Shanghai, China [3]Tongji University Suzhou Institute, Suzhou, Jiangsu, China [4]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Shanghai 200031, China. [*2]Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, 507 Zhengmin Road, Shanghai 2000433, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.

文献详情

相关文献